Hotspots and prospects of esophageal cancer research in China / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 307-311, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-986790
ABSTRACT
Esophageal cancer is a malignant tumor with a high incidence in China. At pesent, advanced esophageal cancer patients are still frequently encountered. The primary treatment for resectable advanced esophageal cancer is surgery-based multimodality therapy, including preoperative neoadjuvant therapy, such as chemotherapy, chemoradiotherapy or chemotherapy plus immunotherapy, followed by radical esophagectomy with thoraco-abdominal two-field or cervico-thoraco-abdominal three-field lymphadenectomy via minimally invasive approach or thoracotomy. In addition, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy, or immunotherapy may also be administered if suggested by postoperative pathological results. Although the treatment outcome of esophageal cancer has improved significantly in China, many clinical issues remain controversial. In this article, we summarize the current hotspots and important issues of esophageal cancer in China, including prevention and early diagnosis, treatment selection for early esophageal cancer, surgical approach selection, lymphadenectomy method, preoperative neoadjuvant therapy, postoperative adjuvant therapy, and nutritional support treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Esofágicas
/
Esofagectomía
/
Quimioterapia Adyuvante
/
Terapia Combinada
/
Terapia Neoadyuvante
/
Quimioradioterapia
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Gastrointestinal Surgery
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS